NCT07217015View on ClinicalTrials.gov

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Atopic Dermatitis
Interventions
DRUG

KT-621

Oral drug

OTHER

Placebo

Oral placebo matched to KT-621

Trial Locations (2)

33137

RECRUITING

Kymera Investigative Site, Miami

58103

RECRUITING

Kymera Investigative Site, Fargo

Sponsors
All Listed Sponsors
lead

Kymera Therapeutics, Inc.

INDUSTRY